Pregnancy and Perinatal Outcome Among Hypothyroid Mothers: A Population-Based Cohort Study.
hypothyroidism
levothyroxine
perinatal
pregnancy
thyroid
Journal
Thyroid : official journal of the American Thyroid Association
ISSN: 1557-9077
Titre abrégé: Thyroid
Pays: United States
ID NLM: 9104317
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
13
11
2018
medline:
18
12
2019
entrez:
13
11
2018
Statut:
ppublish
Résumé
Maternal hypothyroidism has been associated with adverse pregnancy outcomes. A large nationwide register-based cohort with data on medication purchases was established to study the associations between maternal hypothyroidism, levothyroxine (LT4) use, and pregnancy and perinatal complications. The data included all singleton births between 2004 and 2013 (N = 571,785) in Finland. Hypothyroid mothers (n = 16,364) were identified in the Finnish Medical Birth Register. Of these women, 95.8% used LT4 medication, and 37.5% had consistent LT4 use during pregnancy. Hypothyroid mothers were compared to mothers without thyroid disease (N = 550,860) using logistic regression. The main outcome measures were pregnancy and perinatal complications. Maternal hypothyroidism was associated with several pregnancy and perinatal complications, including gestational diabetes mellitus (odds ratio [OR] = 1.19 [confidence interval (CI) 1.13-1.25]), gestational hypertension (OR = 1.20 [CI 1.10-1.30]), severe preeclampsia (OR = 1.38 [CI 1.15-1.65]), cesarean section (OR = 1.22 [CI 1.17-1.27]), preterm births (OR = 1.25 [CI 1.16-1.34]), large-for-gestational age newborns (OR = 1.30 [CI 1.19-1.42]), major congenital anomalies (OR = 1.14 [CI 1.06-1.22]), and neonatal intensive care unit admission (OR = 1.23 [CI 1.17-1.29]). However, among mothers with consistent LT4 purchases, only the associations between gestational diabetes mellitus (OR = 1.12 [CI 1.03-1.22]), cesarean section (OR = 1.13 [CI 1.06-1.21]), neonatal intensive care unit admission (OR = 1.09 [CI 1.01-1.29]), and large-for-gestational age newborns (OR = 1.26 [CI 1.10-1.45]) and maternal hypothyroidism remained. Maternal hypothyroidism is associated with several pregnancy and perinatal complications, but consistent LT4 use may reduce many of the risks.
Sections du résumé
BACKGROUND
Maternal hypothyroidism has been associated with adverse pregnancy outcomes. A large nationwide register-based cohort with data on medication purchases was established to study the associations between maternal hypothyroidism, levothyroxine (LT4) use, and pregnancy and perinatal complications.
METHODS
The data included all singleton births between 2004 and 2013 (N = 571,785) in Finland. Hypothyroid mothers (n = 16,364) were identified in the Finnish Medical Birth Register. Of these women, 95.8% used LT4 medication, and 37.5% had consistent LT4 use during pregnancy. Hypothyroid mothers were compared to mothers without thyroid disease (N = 550,860) using logistic regression. The main outcome measures were pregnancy and perinatal complications.
RESULTS
Maternal hypothyroidism was associated with several pregnancy and perinatal complications, including gestational diabetes mellitus (odds ratio [OR] = 1.19 [confidence interval (CI) 1.13-1.25]), gestational hypertension (OR = 1.20 [CI 1.10-1.30]), severe preeclampsia (OR = 1.38 [CI 1.15-1.65]), cesarean section (OR = 1.22 [CI 1.17-1.27]), preterm births (OR = 1.25 [CI 1.16-1.34]), large-for-gestational age newborns (OR = 1.30 [CI 1.19-1.42]), major congenital anomalies (OR = 1.14 [CI 1.06-1.22]), and neonatal intensive care unit admission (OR = 1.23 [CI 1.17-1.29]). However, among mothers with consistent LT4 purchases, only the associations between gestational diabetes mellitus (OR = 1.12 [CI 1.03-1.22]), cesarean section (OR = 1.13 [CI 1.06-1.21]), neonatal intensive care unit admission (OR = 1.09 [CI 1.01-1.29]), and large-for-gestational age newborns (OR = 1.26 [CI 1.10-1.45]) and maternal hypothyroidism remained.
CONCLUSIONS
Maternal hypothyroidism is associated with several pregnancy and perinatal complications, but consistent LT4 use may reduce many of the risks.
Identifiants
pubmed: 30417761
doi: 10.1089/thy.2018.0311
doi:
Substances chimiques
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM